Revolution Medicines Inc.
Revolution Medicines, Inc. Issues $500 Million Convertible Senior Notes
Summary
On April 17, 2026, Revolution Medicines, Inc. issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033. The Notes will accrue interest at a rate of 0.50% per annum, payable semi-annually in arrears. Noteholders will have the right to convert their Notes into the Company's common stock under certain conditions, with an initial conversion rate of 5.0302 shares per $1,000 principal amount of Notes. The Company may redeem the Notes under specific market conditions and must repurchase them if certain corporate events occur. The Notes are senior, unsecured obligations and are governed by an indenture with U.S. Bank Trust Company, National Association, as trustee.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement